Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

DRAK2 Antikörper (C-Term)

STK17B Reaktivität: Human, Maus WB, IF, IHC (p) Wirt: Kaninchen Polyclonal RB3049 unconjugated
Produktnummer ABIN1882073
  • Target Alle DRAK2 (STK17B) Antikörper anzeigen
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Bindungsspezifität
    • 10
    • 7
    • 6
    • 6
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 342-371, C-Term
    Reaktivität
    • 41
    • 15
    • 8
    • 1
    • 1
    • 1
    Human, Maus
    Wirt
    • 38
    • 2
    • 1
    Kaninchen
    Klonalität
    • 40
    • 1
    Polyklonal
    Konjugat
    • 20
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser DRAK2 Antikörper ist unkonjugiert
    Applikation
    • 29
    • 25
    • 8
    • 3
    • 3
    • 2
    • 2
    Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Aufreinigung
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This DRAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 342-371 amino acids from the C-terminal region of human DRAK2.
    Klon
    RB3049
    Isotyp
    Ig Fraction
    Top Product
    Discover our top product STK17B Primärantikörper
  • Applikationshinweise
    IF: 1:10~50. WB: 1:1000. IHC-P: 1:50~100
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Haltbarkeit
    6 months
  • Mao, Luo, Han, Bertrand, Wu: "Drak2 is upstream of p70S6 kinase: its implication in cytokine-induced islet apoptosis, diabetes, and islet transplantation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 8, pp. 4762-70, (2009) (PubMed).

    Mao, Qiao, Luo, Wu: "Transgenic drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development." in: The Journal of biological chemistry, Vol. 281, Issue 18, pp. 12587-95, (2006) (PubMed).

    Sanjo, Kawai, Akira: "DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis." in: The Journal of biological chemistry, Vol. 273, Issue 44, pp. 29066-71, (1998) (PubMed).

  • Target
    DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
    Andere Bezeichnung
    DRAK2 (STK17B Produkte)
    Synonyme
    zgc:65989 antikoerper, STK17B antikoerper, DRAK2 antikoerper, Drak2 antikoerper, 3110009A03Rik antikoerper, AI120141 antikoerper, serine/threonine kinase 17b (apoptosis-inducing) antikoerper, serine/threonine kinase 17b antikoerper, stk17b antikoerper, STK17B antikoerper, Stk17b antikoerper
    Hintergrund
    DRAK2 is a novel serine/threonine kinase that induces apoptosis via catalytic activity. DRAKs present high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases. DRAK2 is located in nucleus, and the messenger RNA is ubiquitously expressed in human tissues.
    Molekulargewicht
    42344
    NCBI Accession
    NP_004217
    UniProt
    O94768
Sie sind hier:
Kundenservice